Prognose

Das durchschnittliche Kursziel der Analysten beträgt +18,22€(+432,75%). Der Median liegt bei +15,34€(+348,54%).

Kaufen	10
Halten	9
Verkaufen	0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

Revance Announces Blue Lizard® Australian Sunscreen Times Square Takeover to Celebrate National Sunscreen Day
NASHVILLE, Tenn., May 27, 2025 /PRNewswire/ -- Revance is proud to announce that Blue Lizard® Australian Sunscreen, the #1 best-selling mineral SPF brand in the U.S.*, is celebrating National Sunscreen Day on May 27th with a dynamic digital billboard in New York City's Times Square, capping off Skin Cancer Awareness Month and heading into sun season with a bold message: Be Fearless in the Sun. "We're excited to mark National Sunscreen Day in such a powerful way," said Steve Gallopo, Executive Vice President and Chief Commercial Officer, Consumer Skincare. "This billboard is a monumental celebration of our heritage in mineral sun protection and a call to action for everyone to take sun safety seriously." "Our mission is to make sun protection accessible and easy for the whole family," added Nicole Watson, SVP Global Therapeutics Marketing, Consumer Skincare. "This recent rebrand reflects that, with cleaner formulas, enhanced aesthetics, and the same uncompromising SPF 50 protection people have trusted for years." The Times Square billboard showcases Blue Lizard's newly rebranded and reformulated line of mineral sunscreens. The updated formulas feature 100% mineral active ingredients and are free from fragrances, parabens, phthalates, oxybenzone, and octinoxate – offering the same powerful broad-spectrum UVA/UVB protection the brand is known for, now with a cleaner ingredient profile and modern packaging. "UV exposure is cumulative, and daily use of a broad-spectrum mineral sunscreen, like those from Blue Lizard, can significantly reduce the risk of developing skin cancer," said Dr. Aanand Geria, Board Certified Dermatologist. "Blue Lizard is a brand that I feel confident recommending to my patients and using on my own family knowing they will stay protected." As a proud partner of The Skin Cancer Foundation, Blue Lizard is reinforcing its long-standing commitment to sun safety and skin cancer prevention. This Times Square activation amplifies that mission on a national stage – empowering families to enjoy the sun with confidence and the protection they can trust. For more information about Blue Lizard and its full line of products, visit www.bluelizardsunscreen.com. *Revance calculation based on data reported by Circana database in the Mineral Sunscreen category for the 52-week period ending 4/17/2025. Copyright @2025 Circana, LLC. About Blue Lizard®For nearly 30 years, Blue Lizard has been a trusted name in sun protection, offering a comprehensive range of mineral sunscreens designed to safeguard all skin types. Our dermatologist- and pediatrician-recommended 100% mineral formulas are free from fragrances, parabens, and phthalates that can irritate sensitive skin and are free from oxybenzone and octinoxate, aligning with our "We Love the Reef™" initiative to protect delicate marine ecosystems. Featuring Smart Cap® Technology, Blue Lizard product packaging also lets consumers know when harmful UV rays are present and reminds them to reapply. Blue Lizard is owned by Crown Laboratories, Inc., a Revance company. About Revance Revance is a fast-growing global aesthetics and skincare company focused on providing innovative aesthetics and market-leading skincare offerings throughout every stage of life. With a differentiated portfolio of products spanning 60 countries, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and commercialization of new products and treatments. Learn more at Revance.com, RevanceAesthetics.com, CrownLaboratories.com, and CrownAesthetics.com.» Mehr auf prnewswire.com
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Revance Therapeutics, Inc. (NASDAQ:RVNC) on behalf of long-term stockholders following a class action complaint that was filed against Revance on January 3, 2025 with a Class Period from February 29, 2024 to December 6, 2024. Our investigation concerns whether the board of directors of Revance have breached their fiduciary duties to the company.» Mehr auf globenewswire.com
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133949&wire=1 or contact Joseph E. Levi, Esq.» Mehr auf accessnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Revance Therapeutics einen Umsatz von 53,77 Mio€ und ein Nettoeinkommen von −31,53 Mio€

(EUR)	Sep. 2024	YOY
Umsatz	+53,77 Mio	-
Bruttoeinkommen	+37,94 Mio	-
Nettoeinkommen	−31,53 Mio	-
EBITDA	−25,71 Mio	-

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+334,10 Mio€
Anzahl Aktien	104,39 Mio
52 Wochen-Hoch/Tief	+6,63€ - +2,02€
Dividenden	Nein
Beta	0,95
KGV (PE Ratio)	−2,10
KGWV (PEG Ratio)	−0,05
KBV (PB Ratio)	−2,33
KUV (PS Ratio)	+1,54

Unternehmensprofil

Revance Therapeutics, Inc. ist ein Biotechnologieunternehmen, das sich mit der Entwicklung, Herstellung und Vermarktung von Neuromodulatoren für verschiedene ästhetische und therapeutische Indikationen in den Vereinigten Staaten und international beschäftigt. Der führende Medikamentenkandidat des Unternehmens ist DaxibotulinumtoxinA zur Injektion, das klinische Studien der Phase III zur Behandlung von Glabellafalten (Zornesfalten) und zervikaler Dystonie abgeschlossen hat; es befindet sich in klinischen Studien der Phase II zur Behandlung von oberen Gesichtsfalten, mäßigen oder schweren dynamischen Stirnfalten und mäßigen oder schweren seitlichen Canthal-Falten; und es hat klinische Studien der Phase II zur Behandlung von Spastizität der oberen Gliedmaßen und Plantarfasziitis bei Erwachsenen abgeschlossen. Das Unternehmen entwickelt außerdem DaxibotulinumtoxinA in präklinischen Studien zur Behandlung von Migräne sowie ein topisches Programm für verschiedene Indikationen und OnabotulinumtoxinA, ein Biosimilar zu BOTOX. Das Unternehmen hat eine Kooperations- und Lizenzvereinbarung mit Viatris Inc. zur Entwicklung, Herstellung und Vermarktung von OnabotulinumtoxinA. Das Unternehmen war früher als Essentia Biosystems, Inc. bekannt und änderte im April 2005 seinen Namen in Revance Therapeutics, Inc. um. Revance Therapeutics, Inc. wurde 1999 gegründet und hat seinen Hauptsitz in Nashville, Tennessee.